-
Product Name
Anti-FCN1/FCNA antibody
- Documents
-
Description
Rabbit polyclonal to FCN1/FCNA
-
Tested applications
ELISA, IHC-P
-
Species reactivity
Human Ficolin-1 / Ficolin-A
-
Alternative names
Fcn1 antibody; FCN1 antibody; Fcna antibody; FCNM antibody; ficolin 1 antibody; ficolin A antibody; RP23-464C2.11 antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
Produced in rabbits immunized with purified, recombinant Human FCN1 (rh FCN1; NP_001994.2; Met 1-Ala 326). FCN1 specific IgG was purified by human FCN1 affinity chromatography
-
Clonality
Polyclonal
-
Formulation
0.2 μm filtered solution in PBS with 5% trehalose
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human FCN1. The detection limit for Human FCN1 is approximately 0.039 ng/well.
IHC-P: 0.1-2 μg/mL
-
Validations
Ficolin-1 / Ficolin-A / FCN1 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry
Immunochemical staining of human FCN1 in human placenta with rabbit polyclonal antibody (0.2 µg/mL, formalin-fixed paraffin embedded sections). Positive staining was localized to peripheral blood leukocytes.
Ficolin-1 / Ficolin-A / FCN1 Antibody, Rabbit PAb, Antigen Affinity Purified, Immunohistochemistry
Immunochemical staining of human FCN1 in human liver with rabbit polyclonal antibody (0.2 µg/mL, formalin-fixed paraffin embedded sections). Positive staining was localized to peripheral blood leukocytes.
-
Background
Ficolins are humoral molecules of the innate immune systems which recognize carbohydrate molecules on pathogens, apoptotic and necrotic cells. The Ficolin family of proteins are characterized by the presence of a leader peptide, a short N-terminal segment, followed by a collagen-like region, and a C-terminal fibrinogen-like domain. Ficolins are humoral molecules of the innate immune systems which recognize carbohydrate molecules on pathogens, apoptotic and necrotic cells. Three Ficolins have been identified in humans: L-Ficolin, H-Ficolin and M-Ficolin (also referred to as Ficolin-2, -3 and -1, respectively). They are soluble oligomeric defence proteins with lectin-like activity and they are structurally similar to the human collectins, mannan-binding lectin (MBL) and surfactant protein A and D. Dysfunction or abnormal expressions of Ficolins may involved in the pathogenesis of human diseases including infectious and inflammatory diseases, autoimmune disease and clinical syndrome of preeclampsia. They are soluble oligomeric defence proteins with lectin-like activity and they are structurally similar to the human collectins, mannan-binding lectin (MBL) and surfactant protein A and D. Upon recognition of the infectious agent, the Ficolins act through two distinct routes: initiate the lectin pathway of complement activation through attached serine proteases (MASPs), and a primitive opsonophagocytosis thus limiting the infection and concurrently orchestrating the subsequent adaptive clonal immune response. Ficolin-1 (FCN1) is predominantly expressed in the peripheral blood leukocytes.
-
References
- Thiel S. (2007) Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol. 44(16): 3875-88.
- Zhang XL, et al. (2008) Ficolins: structure, function and associated diseases. Adv Exp Med Biol. 632: 105-15.
- Garred P, et al. (2009) MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol. 46(14): 2737-44.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"